Project Grant R01CA310022
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $624K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a $2,554,662 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective March 5, 2026, through February 28, 2031. This comprehensive research initiative focuses on developing biomaterial-enhanced Chimeric Antigen Receptor (CAR) T-cell and Natural Killer T (NKT) cell therapies to improve treatment outcomes for glioblastoma, a highly...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of North Carolina at Chapel Hill a Project Grant of $627,676 under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025 through August 31, 2028. This three-year research initiative focuses on developing and validating genetically-encoded biosensors to characterize intercellular heterogeneity in cell cycle quiescence—specifically the spectrum of quiescent (dormant) states in cancer...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $207,802 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for the period May 1, 2026 through April 30, 2029. The award supports the development of multiplexed multiscale imaging technologies and automated analysis systems designed to advance cellular immunotherapy research. Specifically, the project will develop novel fluorescent...
- Federal Grant Award Summary The University of North Carolina at Asheville received a $428,396 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2029. This three-year award supports fundamental research investigating novel post-translational regulatory mechanisms of G12/13 heterotrimeric G proteins, which have been implicated in driving tumorigenic signaling, metastatic invasiveness, and stem...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of North Carolina at Chapel Hill $384,630 under the Cancer Biology Research program (CFDA 93.396) on April 10, 2026, for a project titled "Identifying Immune-Mediated Mechanisms of RAS Inhibitor Efficacy and Resistance in Pancreatic Cancer." The award, with a completion date of March 31, 2027, funds research designed to elucidate how tumor-immune microenvironment remodeling contributes to the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $223,176 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Duke University on September 10, 2025, with a completion date of April 30, 2028. This F32 postdoctoral fellowship award supports research investigating the role of SMARCAL1 (an annealing helicase) depletion in enhancing immunogenicity within Alternative Lengthening of Telomeres (ALT)-positive high-grade gliomas. The research addresses a...
- Federal Project Grant Award Summary The National Cancer Institute awarded $399,829 to the University of North Carolina at Chapel Hill under the Cancer Biology Research program (CFDA 93.396) for a two-year project (September 1, 2025–August 31, 2027) investigating the role of Fusobacterium nucleatum in breast cancer progression and therapeutic resistance. The research will characterize how this bacterium, detected in approximately 30% of breast cancer cases, alters the tumor microenvironment and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Grant Award Summary The National Cancer Institute awarded a $663,340 Project Grant to the University of California, Berkeley on August 27, 2025, under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The research will elucidate mechanisms by which local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer (NK) cells and CD4 T cells to control tumors that have...
- Federal Project Grant Award Summary The National Cancer Institute awarded University of North Carolina at Charlotte $150,784 under the Cancer Biology Research program (CFDA 93.396) beginning September 1, 2025 and concluding August 31, 2027. This project grant funds fundamental research investigating the interplay between the HSP70 (Heat Shock Protein 70) molecular chaperone and cyclin D1/CLN3 proteins, with implications for understanding cell cycle regulation and potential anticancer therapeutic...